LAG3 and gastric cancer: Another EBV (+) GC patient with spleen and multiple lymph node metastasis was enroled in phase 1 clinical trial of KL-A289 (LAG-3 inhibitor) (Chinadrugtrials.org.cn identifier: CTR20211028).